Anna M. de Kort

646 total citations · 1 hit paper
22 papers, 327 citations indexed

About

Anna M. de Kort is a scholar working on Neurology, Physiology and Molecular Biology. According to data from OpenAlex, Anna M. de Kort has authored 22 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Neurology, 17 papers in Physiology and 7 papers in Molecular Biology. Recurrent topics in Anna M. de Kort's work include Intracerebral and Subarachnoid Hemorrhage Research (21 papers), Alzheimer's disease research and treatments (17 papers) and Cerebrovascular and genetic disorders (9 papers). Anna M. de Kort is often cited by papers focused on Intracerebral and Subarachnoid Hemorrhage Research (21 papers), Alzheimer's disease research and treatments (17 papers) and Cerebrovascular and genetic disorders (9 papers). Anna M. de Kort collaborates with scholars based in Netherlands, United States and United Kingdom. Anna M. de Kort's co-authors include Marcel M. Verbeek, Floris H.B.M. Schreuder, Catharina J.M. Klijn, Lieke Jäkel, H. Bea Kuiperij, Iris Kersten, Isabel Santana, Markus Otto, Patrick Oeckl and Alexander E. Volk and has published in prestigious journals such as Journal of Neurochemistry, Journal of Neurology Neurosurgery & Psychiatry and Journal of Alzheimer s Disease.

In The Last Decade

Anna M. de Kort

21 papers receiving 326 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis

2021 167 citations Lieke Jäkel, Anna M. de Kort et al. Alzheimer s & Dementia profile →

Peers

Anna M. de Kort

PHYSI

NEURO

PMH

NEURO

Jasmin Rahimi Austria

Guro Berge Norway

Sleiman El Jamal United States

Natalia Ermann Germany

Nobuyuki Sodeyama Japan

Carolin Heller United Kingdom

Carmen Castrillo‐Viguera United States

Daniela Díaz‐Lucena Spain

Frank Zamudio United States

María Belén Sánchez‐Saudinós Spain

Jasmin Rahimi Austria

Anna M. de Kort

198 ×1.0

PHYSI

130 ×0.7

NEURO

119 ×1.6

127 ×1.8

PMH

121 ×1.8

NEURO

Citations per year, relative to Anna M. de Kort Anna M. de Kort (= 1×) peers Jasmin Rahimi

Countries citing papers authored by Anna M. de Kort

Since Specialization

Citations

This map shows the geographic impact of Anna M. de Kort's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna M. de Kort with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna M. de Kort more than expected).

Fields of papers citing papers by Anna M. de Kort

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna M. de Kort. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna M. de Kort. The network helps show where Anna M. de Kort may publish in the future.

Co-authorship network of co-authors of Anna M. de Kort

This figure shows the co-authorship network connecting the top 25 collaborators of Anna M. de Kort. A scholar is included among the top collaborators of Anna M. de Kort based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna M. de Kort. Anna M. de Kort is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kort, Anna M. de, Bob Siegerink, Sabine Voigt, et al.. (2024). Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathy. Alzheimer s Research & Therapy. 16(1). 74–74. 3 indexed citations

Kort, Anna M. de, et al.. (2024). Prevalence of Cerebral Amyloid Angiopathy Pathology and Strictly Lobar Microbleeds in East-Asian Versus Western Populations: A Systematic Review and Meta-Analysis. Journal of Stroke. 26(2). 179–189. 7 indexed citations

Berg, E. van den, Iris Kersten, Gunnar Brinkmalm, et al.. (2024). Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy. Journal of Neurochemistry. 168(7). 1254–1264. 3 indexed citations

Kort, Anna M. de, Iris Kersten, Hans J. C. T. Wessels, et al.. (2024). Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients. Acta Neuropathologica Communications. 12(1). 6–6. 7 indexed citations

Jäkel, Lieke, Anna M. de Kort, Iris Kersten, et al.. (2024). Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy. Acta Neuropathologica Communications. 12(1). 103–103. 3 indexed citations

Kuiperij, H. Bea, Anna M. de Kort, Iris Kersten, et al.. (2024). Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy. Alzheimer s Research & Therapy. 16(1). 108–108.

Kort, Anna M. de, H. Bea Kuiperij, Lieke Jäkel, et al.. (2024). The relation of a cerebrospinal fluid profile associated with Alzheimer’s disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy. Alzheimer s Research & Therapy. 16(1). 99–99. 2 indexed citations

Voigt, Sabine, Emma A. Koemans, Anna M. de Kort, et al.. (2024). Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy. Alzheimer s Research & Therapy. 16(1). 86–86. 8 indexed citations

Berg, E. van den, Johanna Nilsson, Iris Kersten, et al.. (2023). Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease. Journal of Alzheimer s Disease. 92(2). 467–475. 4 indexed citations

10.

Kort, Anna M. de, Lieke Jäkel, Iris Kersten, et al.. (2023). Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy. Alzheimer s Research & Therapy. 15(1). 26–26. 6 indexed citations

11.

Kort, Anna M. de, H. Bea Kuiperij, Lieke Jäkel, et al.. (2023). Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy. Alzheimer s Research & Therapy. 15(1). 102–102. 8 indexed citations

12.

Oeckl, Patrick, Sarah Anderl‐Straub, Christine A. F. Von Arnim, et al.. (2022). Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology Neurosurgery & Psychiatry. 93(6). 659–667. 64 indexed citations

13.

Zhu, Xiaoyue, Anna M. de Kort, Tainá M. Marques, et al.. (2022). Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy. Neuropathology and Applied Neurobiology. 48(5). e12804–e12804. 2 indexed citations

14.

Kort, Anna M. de, H. Bea Kuiperij, Daniel Alcolea, et al.. (2021). Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy. Alzheimer s Research & Therapy. 13(1). 160–160. 6 indexed citations

15.

Marazuela, Paula, Montse Solé, Jessica Camacho, et al.. (2021). MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy. Acta Neuropathologica Communications. 9(1). 154–154. 14 indexed citations

16.

Zhu, Xiaoyue, Anna M. de Kort, Tainá M. Marques, et al.. (2021). Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy. Alzheimer s & Dementia. 17(S4). 1 indexed citations

17.

Verbeek, Marcel M., Anna M. de Kort, Marieke J.H. Wermer, et al.. (2021). Amyloid‐βeta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls. Alzheimer s & Dementia. 17(S4). 1 indexed citations

18.

Kort, Anna M. de, Lieke Jäkel, Catharina J.M. Klijn, Floris H.B.M. Schreuder, & Marcel M. Verbeek. (2021). Prevalence of sporadic cerebral amyloid angiopathy: A systematic review and meta‐analysis. Alzheimer s & Dementia. 17(S10). 2 indexed citations

19.

Kort, Anna M. de, et al.. (2020). Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy. Alzheimer s & Dementia. 16(S4). 1 indexed citations

20.

Kuiperij, H. Bea, Anna M. de Kort, Iris Kersten, et al.. (2020). Platelet‐derived growth factor receptor‐beta as a potential CSF biomarker for Alzheimer’s disease. Alzheimer s & Dementia. 16(S5). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact